86 related articles for article (PubMed ID: 17555911)
1. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
Kaas R; Muller SH; Hart AA; Rutgers EJ
Eur J Surg Oncol; 2008 May; 34(5):501-7. PubMed ID: 17555911
[TBL] [Abstract][Full Text] [Related]
2. [Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer].
Kaas R; Rutgers EJ
Ned Tijdschr Geneeskd; 2008 Oct; 152(43):2317-8. PubMed ID: 19024059
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
[TBL] [Abstract][Full Text] [Related]
4. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
[TBL] [Abstract][Full Text] [Related]
5. MRI screening in a clinic population with a family history of breast cancer.
Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
[TBL] [Abstract][Full Text] [Related]
6. [Breast self-examination also valuable in women participating in a screening programme].
Zonderhuis BM; Meijer S; Been J; Groot JJ; Langenhorst F; van den Tol MP
Ned Tijdschr Geneeskd; 2008 Oct; 152(43):2341-5. PubMed ID: 19024066
[TBL] [Abstract][Full Text] [Related]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
8. Use of breast MRI surveillance in women at high risk for breast cancer: a single-institutional experience.
Elmore L; Margenthaler JA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():263-7. PubMed ID: 20853044
[TBL] [Abstract][Full Text] [Related]
9. Screening for hereditary breast cancer.
Dent R; Warner E
Semin Oncol; 2007 Oct; 34(5):392-400. PubMed ID: 17920893
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.
Olawaiye A; Caesar L; Walsh D; Lyman M; Yeh J; Rodabaugh K; Marchetti D; Lele S; Odunsi K
Gynecol Oncol; 2004 Sep; 94(3):796-802. PubMed ID: 15350375
[TBL] [Abstract][Full Text] [Related]
11. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
12. Hereditary risk of breast cancer: not only BRCA.
Turchetti D; Cortesi L; Federico M; Romagnoli R; Silingardi V
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):17-21. PubMed ID: 12585649
[TBL] [Abstract][Full Text] [Related]
13. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
[TBL] [Abstract][Full Text] [Related]
14. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
[TBL] [Abstract][Full Text] [Related]
15. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
16. The development of interval breast malignancies in patients with BRCA mutations.
Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
[TBL] [Abstract][Full Text] [Related]
17. Hereditary breast cancer growth rates and its impact on screening policy.
Tilanus-Linthorst MM; Kriege M; Boetes C; Hop WC; Obdeijn IM; Oosterwijk JC; Peterse HL; Zonderland HM; Meijer S; Eggermont AM; de Koning HJ; Klijn JG; Brekelmans CT
Eur J Cancer; 2005 Jul; 41(11):1610-7. PubMed ID: 15978801
[TBL] [Abstract][Full Text] [Related]
18. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
Rijnsburger AJ; Obdeijn IM; Kaas R; Tilanus-Linthorst MM; Boetes C; Loo CE; Wasser MN; Bergers E; Kok T; Muller SH; Peterse H; Tollenaar RA; Hoogerbrugge N; Meijer S; Bartels CC; Seynaeve C; Hooning MJ; Kriege M; Schmitz PI; Oosterwijk JC; de Koning HJ; Rutgers EJ; Klijn JG
J Clin Oncol; 2010 Dec; 28(36):5265-73. PubMed ID: 21079137
[TBL] [Abstract][Full Text] [Related]
20. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
